Thomas John Dietz, Director at Eiger BioPharmaceuticals, Inc. (EIGR), bought 4,000 shares at $13.94 ($56K) on 2020-01-10, disclosed to the SEC on 2020-01-13.
Open-market purchase of $56k EIGR by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade B.
Nothing distinguishes this filing.
| Filing → |
| EIGR | SELL | 2022-12-27 | $26K | — | Filing → |
| EIGR | BUY | 2021-04-12 | $21K | — | Filing → |
| EIGR | BUY | 2020-03-17 | $5K | — | Filing → |